Stifel maintains Buy on Contineum stock after phase 2 trial miss

Stifel has maintained its Buy rating and $28.00 price target for Contineum Therapeutics (NASDAQ:CTNM) despite the company's failure to meet the primary endpoint in a phase 2 trial for major depressive disorder. The trial, focusing on Contineum's selective M1R antagonist PIPE-307/JNJ-5120, did not show a statistically significant change from baseline in MADRS at Day 5.

Nevertheless, the company remains optimistic about the potential next steps for development of the program based on the ongoing analysis of the data. Contineum's strong financial position, as indicated by a current ratio above 37 and more cash than debt on its balance sheet, provides a solid foundation for the investment thesis.

The firm's focus on the LPA1 antagonist program for idiopathic pulmonary fibrosis is seen as the primary value driver for the stock, with Bristol Myers Squibb's upcoming phase 3 data for admilparant expected by year-end. The success of this program could positively impact Contineum's molecule PIPE-791, currently in phase 2 trials with potential best-in-class attributes.

Contineum's recent publication of a manuscript detailing the discovery and characterization of PIPE-791 further demonstrates the company's commitment to drug discovery and clinical trials in the treatment of fibrotic conditions.